Status: Recruiting
Efficacy, Safety and Pharmacokinetics of DTG with RIF
The overall aim of the project is to evaluate optimal DTG dose for the combined treatment of TB and HIV infections with RIF based anti-TB therapy. This Stage II trial will determine precisely the PK parameters of DTG in combination with RIF regimen in Thai HIV/TB co-infected patients. After the optimal dose of DTG has been found, it will be further tested in a larger Stage III trial to assess its safety, tolerability and efficacy when used with RIF based regimen.
Participants needed: 200
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: The HIV Netherlands Australia Thailand Research CollaborationUpdated: Oct 2, 2024Locations: 10
Eligibility criteria
documented HIV positive [+10]
Have documented history of HIV treatment failure or HIV mutation to NRTI, NNRTI,... [+9]